Innate Pharma (IPHA) Current Deferred Revenue (2017 - 2025)
Innate Pharma's (IPHA) quarterly Current Deferred Revenue came in at $3.3 million in Q4 2025, up 399.57% YoY from $658254.8 in Q4 2024, and up 416.0% on a QoQ basis from $637293.3 in Q2 2025.
Innate Pharma (IPHA) Current Deferred Revenue (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Current Deferred Revenue data on file, last reported at $3.3 million in Q4 2025.
- Quarterly Current Deferred Revenue rose 399.57% year-over-year to $3.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.3 million (up 399.57% YoY) and the FY2025 annual result came in at $3.3 million, up 399.57% from the prior year.
- Current Deferred Revenue grew to $3.3 million in Q4 2025, from $637293.3 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $78.0 million in Q2 2022 to a low of $637293.3 in Q2 2025.
- A 5-year average of $28.2 million and a median of $10.5 million in 2021 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2021 — Current Deferred Revenue slumped 99.87% — and 2025, when it soared 399.57%.
- Tracing IPHA's Current Deferred Revenue over 5 years: stood at $14.3 million in 2021, then tumbled by 53.2% to $6.7 million in 2022, then decreased by 5.71% to $6.3 million in 2023, then plunged by 89.57% to $658254.8 in 2024, then soared by 399.57% to $3.3 million in 2025.
- The last three Current Deferred Revenue figures came in at $3.3 million (Q4 2025), $637293.3 (Q2 2025), and $658254.8 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.29 Mn |
| Jun 30, 2025 | 637,293.30 |
| Dec 31, 2024 | 658,254.77 |
| Jun 30, 2024 | 56.16 Mn |
| Dec 31, 2023 | 6.31 Mn |
| Jun 30, 2023 | 61.04 Mn |
| Dec 31, 2022 | 6.69 Mn |
| Jun 30, 2022 | 78.02 Mn |
| Dec 31, 2021 | 14.30 Mn |
| Jun 30, 2021 | 55.32 Mn |
| Dec 31, 2020 | 13.47 Mn |
| Jun 30, 2020 | 41.58 Bn |
| Dec 31, 2019 | 98.64 Mn |
| Dec 31, 2018 | 171.43 Mn |
| Dec 31, 2017 | 56.41 Mn |